4 completed, 2 enrolling by invitation, 1 recruiting. 5 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Enrolling by invitation 1, Recruiting 1 |
| Phase 2 | 3 | Enrolling by invitation 2, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Nasus Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg - Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV) | Phase 1 | Recruiting | Nasus Pharma | 12 | 2026-09-15 | 2026-10-09 |
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC - Anaphylaxis, Allergy | Phase 1 / Phase 2 | Enrolling by invitation | Nasus Pharma | 50 | 2025-11-03 | 2025-11-14 |
| FMXIN002 in Patients at Risk of Anaphylaxis Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product - Anaphylaxis Food | Phase 2 / Phase 3 | Enrolling by invitation | Nasus Pharma | 30 | 2025-06-12 | 2025-07-01 |
| Comparative Bioavailability of Intranasal Epinephrine A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg - Anaphylaxis, Anaphylactic Reaction | Phase 1 / Phase 2 | Completed | Nasus Pharma | 12 | 2023-08-22 | 2025-06-18 |
| COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). TaffiX™ - COVID-19, Upper Respiratory Tract Infections | Not applicable | Completed | Nasus Pharma | 693 | 2021-05-19 | 2022-03-10 |
| A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Nasus Pharma FMXIN001, Nasal Naloxone liquid spray - Opioid Overdose | Phase 1 | Completed | Nasus Pharma | 46 | 2021-01-31 | 2022-05-02 |
| Bioavailability of Nasal Epinephrine Epinephrine Nasal Product, 1.6 mg, Epinephrine nasal product, 1.6 mg + allergen, Epinephrine Injection 0.3 mg - Anaphylaxis | Phase 1 | Completed | Nasus Pharma | 12 | 2020-11-01 | 2024-01-05 |
Anaphylaxis (3) · COVID-19 (1) · Hypersensitivity (1) · Opiate Overdose (1) · Postoperative Nausea and Vomiting (1) · Respiratory Tract Infections (1) · Virus Diseases (1) · Vomiting (1)
Epinephrine (4) · Allergens (1) · Infusions, Intravenous (1) · Injections (1) · Naloxone (1)
Israel (4) · Canada (2) · Bulgaria (1)
Arnon Elizur, Prof. (1) · Emil Kolev, MD (1) · Janice Faulknor, MD, CCFP (1) · Mark L Freedman, MD, FRCPC (1) · Yoseph Caraco, Prof. (1) · Yoseph Caraco, Professor (1)